Darunavir/Ritonavir in HIV-1-Infected Pregnant Women Darunavir/Ritonavir in HIV-1-Infected Pregnant Women
How does pregnancy affect the pharmacokinetics of this antiretroviral regimen?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 9, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Ombitasvir/Paritaprevir/Ritonavir Regimen for Hepatitis C Ombitasvir/Paritaprevir/Ritonavir Regimen for Hepatitis C
This combination drug regimen proved highly effective for treatment of chronic HCV infection, even in difficult-to-treat populations and individuals with advanced disease.Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 8, 2016 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news
A Study of DRV/r for HIV Post-Exposure Prophylaxis A Study of DRV/r for HIV Post-Exposure Prophylaxis
Should ritonavir-boosted darunavir be considered as part of a HIV post-exposure prophylaxis regimen?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 4, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
NORTH CHICAGO, Ill., Sept. 23, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritona... Biopharmaceuticals AbbVie, hepatitis C, VIEKIRAX, EXVIERA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 23, 2016 Category: Pharmaceuticals Source Type: news
Improvement of Lipoatrophy by Switching From EFV to LPV/r Improvement of Lipoatrophy by Switching From EFV to LPV/r
Switching HIV patients with lipoatrophy from efavirenz to lopinavir/ritonavir may affect positive changes in limb fat.HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents
Could oral contraceptives containing ethinyl estradiol/desogestrel compromise the effectiveness of lopinavir/ritonavir-based therapy?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 24, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
NORTH CHICAGO, Ill., July 25, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for VIEKIRA XR (... Biopharmaceuticals, FDAAbbVie, VIEKIRA XR, VIEKIRA PAK, hepatitis C (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 26, 2016 Category: Pharmaceuticals Source Type: news
AbbVie Receives U.S. FDA Approval of Once-Daily Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
NORTH CHICAGO, Ill., July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Viekira XR (dasabuvir,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 25, 2016 Category: Drugs & Pharmacology Source Type: news
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
NORTH CHICAGO, Ill., July 25, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has... Biopharmaceuticals, RegulatoryAbbVie, hepatitis C, VIEKIRAX (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2016 Category: Pharmaceuticals Source Type: news
FDA Clears Darunavir (Prezista) for Pregnant Women With HIV FDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. < br / > < i > FDA Approvals < /i > (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
FDA Clears Darunavir (Prezista) for Pregnant Women With HIVFDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
ViiV reports ARIA Phase IIIb trial shows superior efficacy for Triumeq to treat HIV
ViiV Healthcare reported that phase IIIb of the ARIA study showed superior efficacy for Triumeq (dolutegravir / abacavir / lamivudine) compared with atazanavir boosted with ritonavir (ATV/r), along with tenofovir disoproxil fumarate / emtricitabine (… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2016 Category: Pharmaceuticals Source Type: news
Technivie (Ombitasvir, Paritaprevir and Ritonavir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2016 Category: Drugs & Pharmacology Source Type: news
Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir tablets; Dasabuvir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2016 Category: Drugs & Pharmacology Source Type: news
AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
VIEKIRAX and EXVIERA achieved 96 percent SVR12 in genotype 1 and 100 percent in genotype 4 chronic hepatitis C virus infected patients in a large ongoing real-world study(1)
Data support findings from previous HCV Phase 3 clinical trials with VIEKIRAX a... BiopharmaceuticalsAbbVie, hepatitis C, VIEKIRAX, EXVIERA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 15, 2016 Category: Pharmaceuticals Source Type: news
